TY - JOUR
T1 - Surveillance of COVID-19 vaccines
T2 - A comprehensive analysis of the first immunization drive in Ecuador
AU - Orellana-Manzano, Andrea
AU - Garcia-Angulo, Andrea C.
AU - Cordeiro, Fernanda B.
AU - Carvajal-Aldaz, Diana
AU - Centeno, Elizabeth
AU - Vizcaíno, María J.
AU - Poveda, Sebastián
AU - Garcia, Merly
AU - Matías-De la Cruz, Carmen
AU - Andrade-Molina, Derly
AU - Mirabá, Mariuxi
AU - Mehta, Saurabh
AU - Cárdenas, Washington B.
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/3/30
Y1 - 2024/3/30
N2 - The initial phase of the COVID-19 vaccination in Ecuador occurred between April and November 2021. Initially, it focused on priority populations, including health professionals and other front-line workers. During this period, there was limited knowledge about the vaccine's adverse effects. A non-probability, observational study was conducted among university staff in Guayaquil, Ecuador, who received the AstraZeneca vaccine (n = 423) between April and November 2021. This study aimed to compare the acute adverse reactions by doses and to report the incidence of long-term adverse reactions within the AstraZeneca group. As a result, comparing acute adverse reactions between doses, the odds ratio for local pain, headache, muscle pain, fever, and chills are statistically higher after the first dose than the second dose. Survival curves indicated these symptoms appeared mainly within the first 6 h post-vaccination. This is the first pharmacovigilance study from Ecuador that analyzes survival probabilities for the AstraZeneca vaccine's adverse effects.
AB - The initial phase of the COVID-19 vaccination in Ecuador occurred between April and November 2021. Initially, it focused on priority populations, including health professionals and other front-line workers. During this period, there was limited knowledge about the vaccine's adverse effects. A non-probability, observational study was conducted among university staff in Guayaquil, Ecuador, who received the AstraZeneca vaccine (n = 423) between April and November 2021. This study aimed to compare the acute adverse reactions by doses and to report the incidence of long-term adverse reactions within the AstraZeneca group. As a result, comparing acute adverse reactions between doses, the odds ratio for local pain, headache, muscle pain, fever, and chills are statistically higher after the first dose than the second dose. Survival curves indicated these symptoms appeared mainly within the first 6 h post-vaccination. This is the first pharmacovigilance study from Ecuador that analyzes survival probabilities for the AstraZeneca vaccine's adverse effects.
KW - AstraZeneca
KW - COVID-19
KW - Ecuador
KW - Immunization
KW - Vaccine
KW - pharmacovigilance
UR - https://www.scopus.com/pages/publications/85187978793
U2 - 10.1016/j.heliyon.2024.e27464
DO - 10.1016/j.heliyon.2024.e27464
M3 - Artículo
AN - SCOPUS:85187978793
SN - 2405-8440
VL - 10
JO - Heliyon
JF - Heliyon
IS - 6
M1 - e27464
ER -
